Sorrento Therapeutics (SRNE) 5.80 $SRNE
Sorrento Therapeutics Announces Poster Presentations on its Anti-c-Met/PD-L1 Bispecific Antibodies and Anti-c-Met-Antibody Drug Conjugate at the 37th Annual San Antonio Breast Cancer Symposium
PR Newswire - Mon Dec 08, 8:15AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that it will present preclinical data on their bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs) against c-Met in breast cancer at the 37th Annual San Antonio Breast Cancer Symposium in San Antonio, Texas. Highlights of the findings include preclinical data on generation and evaluation of: i) anti-c-Met/anti-PD-L1 and anti-c-Met/anti-ErbB3 BsAbs, and ii) an anti-c-Met ADC as new immunotherapeutic strategies in breast cancer.
SRNE: 5.80 (+0.37)
Sorrento To Present At The 2014 Oppenheimer Healthcare Conference
PR Newswire - Wed Dec 03, 8:30AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, will present at the 2014 Oppenheimer Healthcare Conference on Thursday, December 11, 2014 at 2:45 pm ET in the Act I Room at the Crowne Plaza Hotel in New York City.
SRNE: 5.80 (+0.37)
Initial Pharmacokinetic Data From TRIBECA Study Support Potential For Bioequivalence Between Cynviloq And Albumin-Bound Paclitaxel
PR Newswire Europe - Wed Nov 26, 1:31PM CST
Sorrento Therapeutics, Inc. , an oncology company developing new treatments for cancer and associated pain, announced today positive results from recently analyzed pharmacokinetic (PK) data from the first eight (
patients enrolled in its ongoing TRIBECA(TM) (TRIal establishing BE between Cynviloq(TM) and Albumin-bound paclitaxel) registrational trial. The data from these patients supports earlier completion of the study with the aim of seeking to establish bioequivalence (BE) to albumin-bound paclitaxel to obtain Food and Drug Administration (FDA) marketing approval for Cynviloq (paclitaxel polymeric micelle for injection).
SRNE: 5.80 (+0.37)
Rolling With Biotech's Regulatory Punches: Chen Lin
Life Sciences Report - Seeking Alpha - Tue Nov 25, 3:36PM CST
Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report , Chen Lin, publisher of the investor newsletter What is...
ACRX: 6.40 (unch), BMRN: 91.52 (-1.38), RNA: 18.76 (-0.21), SRPT: 13.97 (-0.33), MRK: 57.72 (-1.62), NLNK: 35.69 (+0.27), GSK: 42.42 (-0.93), SRNE: 5.80 (+0.37), NEPT: 1.96 (-0.02), CELG: 114.49 (-2.25)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 57.72 (-1.62), INCY: 74.65 (-1.27), CLDX: 18.03 (-0.16), NLNK: 35.69 (+0.27), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93), SRNE: 5.80 (+0.37)
Sorrento To Present At The 2014 Stifel Healthcare Conference
PR Newswire - Wed Nov 12, 10:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), today announced that Dr. Henry Ji, President and Chief Executive Officer, will present on Tuesday, November 18, 2014 at 3:00 pm ET in the Winslow Room at the New York Palace Hotel in New York City.
SRNE: 5.80 (+0.37)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 13.82 (-0.86), PFE: 30.95 (-0.70), AMGN: 164.53 (-1.55), AXN: 0.30 (unch), SRNE: 5.80 (+0.37), NKTR: 15.31 (-0.29), EGLT: 6.26 (+0.19), AZN: 71.80 (-1.80), VBAY: ()
Sorrento and Lee's Pharmaceutical Enter into Exclusive China Licensing Agreement to Develop and Commercialize Anti-PD-L1 antibody
PR Newswire - Fri Oct 03, 1:41PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that China Oncology Focus Limited, an Affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharma), a public biopharmaceutical company listed on the main board of Hong Kong Stock Exchange (0950) with over 20 years of operation in China's pharmaceutical industry, has licensed Sorrento's fully human immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014.
SRNE: 5.80 (+0.37)
Sorrento Therapeutics to Present at Two Healthcare Conferences
PR Newswire - Fri Sep 05, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, is scheduled to present a corporate overview at two upcoming conferences.
SRNE: 5.80 (+0.37)
Sorrento secures NIH grant to advance WISP1 in the Idiopathic Pulmonary Fibrosis programme
M2 - Wed Aug 27, 6:07AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) reported on Tuesday the receipt of a Small Business Innovation Research (SBIR) Phase 1 grant to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF).
SRNE: 5.80 (+0.37)
Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)
PR Newswire - Tue Aug 26, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans. As this disease progresses, scarring in the lungs increases and patients gradually lose the ability to breathe, leading ultimately to death in two to five years after diagnosis.
SRNE: 5.80 (+0.37)
Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics
PR Newswire - Mon Aug 18, 6:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that data published in the Proceedings of the National Academy of Sciences (PNAS)1 demonstrate the potential for the MYC inhibitors that Sorrento licensed from The Scripps Research Institute (TSRI)2. The TSRI research team, led by Professors Kim D. Janda and Peter K. Vogt, reported in the study that function of the MYC regulator could be inhibited with small molecule compounds in cell culture and importantly in an experimental cancer animal model.
SRNE: 5.80 (+0.37)
Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors
PR Newswire - Fri Aug 08, 4:00PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of industry veteran Douglas Ebersole to its Board of Directors.
SRNE: 5.80 (+0.37), PDLI: 7.41 (-0.08)
Sorrento condoles sudden death of its EVP Amar Singh
M2 - Fri Aug 01, 8:06AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) disclosed on Thursday the demise of Amar Singh, chief business officer and executive vice president, suddenly and unexpectedly on 30 July 2014.
SRNE: 5.80 (+0.37)
Sorrento Announces the Unexpected Death of its Chief Business Officer
PR Newswire - Thu Jul 31, 4:38PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice President. Mr. Singh died suddenly and unexpectedly of apparent natural causes on July 30.
SRNE: 5.80 (+0.37)
Sorrento wins National Institutes of Health's grant for development of small molecule Myc inhibitor
M2 - Tue Jul 22, 8:30AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) reported on Monday the receipt of the non-dilutive funding for the development of the small molecule inhibitor targeting the important oncogenic transcription factor Myc.
SRNE: 5.80 (+0.37)
Sorrento Awarded up to $2.6 Million from the National Institutes of Health (NIH) for the Development of New Anti-bacterial Bispecific Antibodies and Antibody Formulated Drug Conjugates
PR Newswire - Tue Jul 01, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received two NIH small business grants which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento's highly diverse, fully human G-MAB® library and proprietary antibody conjugation technology platforms have broad applications beyond oncology, including other therapeutic areas such as anti-infectives and auto-immune diseases.
SRNE: 5.80 (+0.37)
BTV Reports on Roche, Sorrento Therapeutics Takes on a Goliath, Plus Biotech Up-and-Comers
Marketwire - Thu Jun 26, 5:01AM CDT
BTV-Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.
SRNE: 5.80 (+0.37), CGIX: 6.30 (unch)
Sorrento Therapeutics Announces Poster Presentations on its Anti-c-Met/PD-L1 Bispecific Antibodies and Anti-c-Met-Antibody Drug Conjugate at the 37th Annual San Antonio Breast Cancer Symposium
PR Newswire - Mon Dec 08, 8:15AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that it will present preclinical data on their bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs) against c-Met in breast cancer at the 37th Annual San Antonio Breast Cancer Symposium in San Antonio, Texas. Highlights of the findings include preclinical data on generation and evaluation of: i) anti-c-Met/anti-PD-L1 and anti-c-Met/anti-ErbB3 BsAbs, and ii) an anti-c-Met ADC as new immunotherapeutic strategies in breast cancer.
SRNE: 5.80 (+0.37)
Sorrento To Present At The 2014 Oppenheimer Healthcare Conference
PR Newswire - Wed Dec 03, 8:30AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, will present at the 2014 Oppenheimer Healthcare Conference on Thursday, December 11, 2014 at 2:45 pm ET in the Act I Room at the Crowne Plaza Hotel in New York City.
SRNE: 5.80 (+0.37)
Initial Pharmacokinetic Data From TRIBECA Study Support Potential For Bioequivalence Between Cynviloq And Albumin-Bound Paclitaxel
PR Newswire Europe - Wed Nov 26, 1:31PM CST
Sorrento Therapeutics, Inc. , an oncology company developing new treatments for cancer and associated pain, announced today positive results from recently analyzed pharmacokinetic (PK) data from the first eight (
patients enrolled in its ongoing TRIBECA(TM) (TRIal establishing BE between Cynviloq(TM) and Albumin-bound paclitaxel) registrational trial. The data from these patients supports earlier completion of the study with the aim of seeking to establish bioequivalence (BE) to albumin-bound paclitaxel to obtain Food and Drug Administration (FDA) marketing approval for Cynviloq (paclitaxel polymeric micelle for injection). SRNE: 5.80 (+0.37)
Rolling With Biotech's Regulatory Punches: Chen Lin
Life Sciences Report - Seeking Alpha - Tue Nov 25, 3:36PM CST
Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report , Chen Lin, publisher of the investor newsletter What is...
ACRX: 6.40 (unch), BMRN: 91.52 (-1.38), RNA: 18.76 (-0.21), SRPT: 13.97 (-0.33), MRK: 57.72 (-1.62), NLNK: 35.69 (+0.27), GSK: 42.42 (-0.93), SRNE: 5.80 (+0.37), NEPT: 1.96 (-0.02), CELG: 114.49 (-2.25)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 57.72 (-1.62), INCY: 74.65 (-1.27), CLDX: 18.03 (-0.16), NLNK: 35.69 (+0.27), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93), SRNE: 5.80 (+0.37)
Sorrento To Present At The 2014 Stifel Healthcare Conference
PR Newswire - Wed Nov 12, 10:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), today announced that Dr. Henry Ji, President and Chief Executive Officer, will present on Tuesday, November 18, 2014 at 3:00 pm ET in the Winslow Room at the New York Palace Hotel in New York City.
SRNE: 5.80 (+0.37)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 13.82 (-0.86), PFE: 30.95 (-0.70), AMGN: 164.53 (-1.55), AXN: 0.30 (unch), SRNE: 5.80 (+0.37), NKTR: 15.31 (-0.29), EGLT: 6.26 (+0.19), AZN: 71.80 (-1.80), VBAY: ()
Sorrento and Lee's Pharmaceutical Enter into Exclusive China Licensing Agreement to Develop and Commercialize Anti-PD-L1 antibody
PR Newswire - Fri Oct 03, 1:41PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that China Oncology Focus Limited, an Affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharma), a public biopharmaceutical company listed on the main board of Hong Kong Stock Exchange (0950) with over 20 years of operation in China's pharmaceutical industry, has licensed Sorrento's fully human immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014.
SRNE: 5.80 (+0.37)
Sorrento Therapeutics to Present at Two Healthcare Conferences
PR Newswire - Fri Sep 05, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, is scheduled to present a corporate overview at two upcoming conferences.
SRNE: 5.80 (+0.37)
Sorrento secures NIH grant to advance WISP1 in the Idiopathic Pulmonary Fibrosis programme
M2 - Wed Aug 27, 6:07AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) reported on Tuesday the receipt of a Small Business Innovation Research (SBIR) Phase 1 grant to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF).
SRNE: 5.80 (+0.37)
Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)
PR Newswire - Tue Aug 26, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans. As this disease progresses, scarring in the lungs increases and patients gradually lose the ability to breathe, leading ultimately to death in two to five years after diagnosis.
SRNE: 5.80 (+0.37)
Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics
PR Newswire - Mon Aug 18, 6:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that data published in the Proceedings of the National Academy of Sciences (PNAS)1 demonstrate the potential for the MYC inhibitors that Sorrento licensed from The Scripps Research Institute (TSRI)2. The TSRI research team, led by Professors Kim D. Janda and Peter K. Vogt, reported in the study that function of the MYC regulator could be inhibited with small molecule compounds in cell culture and importantly in an experimental cancer animal model.
SRNE: 5.80 (+0.37)
Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors
PR Newswire - Fri Aug 08, 4:00PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of industry veteran Douglas Ebersole to its Board of Directors.
SRNE: 5.80 (+0.37), PDLI: 7.41 (-0.08)
Sorrento condoles sudden death of its EVP Amar Singh
M2 - Fri Aug 01, 8:06AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) disclosed on Thursday the demise of Amar Singh, chief business officer and executive vice president, suddenly and unexpectedly on 30 July 2014.
SRNE: 5.80 (+0.37)
Sorrento Announces the Unexpected Death of its Chief Business Officer
PR Newswire - Thu Jul 31, 4:38PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice President. Mr. Singh died suddenly and unexpectedly of apparent natural causes on July 30.
SRNE: 5.80 (+0.37)
Sorrento wins National Institutes of Health's grant for development of small molecule Myc inhibitor
M2 - Tue Jul 22, 8:30AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) reported on Monday the receipt of the non-dilutive funding for the development of the small molecule inhibitor targeting the important oncogenic transcription factor Myc.
SRNE: 5.80 (+0.37)
Sorrento Awarded up to $2.6 Million from the National Institutes of Health (NIH) for the Development of New Anti-bacterial Bispecific Antibodies and Antibody Formulated Drug Conjugates
PR Newswire - Tue Jul 01, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received two NIH small business grants which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento's highly diverse, fully human G-MAB® library and proprietary antibody conjugation technology platforms have broad applications beyond oncology, including other therapeutic areas such as anti-infectives and auto-immune diseases.
SRNE: 5.80 (+0.37)
BTV Reports on Roche, Sorrento Therapeutics Takes on a Goliath, Plus Biotech Up-and-Comers
Marketwire - Thu Jun 26, 5:01AM CDT
BTV-Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.
SRNE: 5.80 (+0.37), CGIX: 6.30 (unch)
